Is mammographic density, as currently measured, a robust surrogate marker for breast cancer?
In order to determine current beliefs concerning the relevance of breast mammographic percent density (MPD) as a surrogate marker for breast cancer, the panel and the delegates completed a questionnaire. There was general agreement between the panel and delegates on most aspects, although the delegates were unsure whether high breast MPD is a contraindication for hormone therapy and tended to err on the side of caution in suggesting that estrogen and estrogen/progestogen therapy should be stopped before screening mammography. The overall consensus of the panel and the delegates was that breast MPD should become an important clinical tool, and that carefully designed studies are needed to determine exactly how it can be best used to guide clinical decision-making.
Related Questions
- Currently, I take extra Calcium to increase bone density and I’m taking CoQ10 for heart health. Will I be able to eliminate those supplements from my daily nutritional regime?
- Does breast size modify the association between mammographic density and breast cancer risk?
- How was density measured for each site?
